Clinical trial design, clinical advice to patients, and clinical decision-making: not the same thing at all

In a recent opinion piece in the Journal of Clinical Oncology, Dr. Anthony D’Amico (a prostate cancer specialist for whom we have great respect) has again aired his concerns about risk for progression to metastatic disease among men on active surveillance. … READ MORE …

Stopping metastasis before it even begins … Can we do that?

The idea that one could stop the initiation of prostate cancer metastasis before it even starts is fundamental to the idea that we might be able to eliminate prostate cancer as a cause of death. And it’s as true for prostate cancer as it is for nearly every other form of cancer. The problem is that we don’t yet know why prostate cancer metastasizes … and many suspect there may be more than one reason. … READ MORE …

Starting the new year with two of the usual controversies

Strictly speaking, JAMA Oncology actually ended the old year (in its issue on December 29, 2016), rather than beginning the new one, with two articles, a letter to the editor, and an editorial that deal with two of the more controversial issues that affect the way we think about the management of prostate cancer. … READ MORE …

Management of men with bone metastasis over time

A new review article in issue 2 of Everyday Urology addresses the topic of bone mets, quality of life, and related factors in the management of advanced and metastatic prostate cancer over time. … READ MORE …

ADT + sipuleucel-T in treatment of hormone-sensitive prostate cancer

One of the major unanswered questions at this time is whether immunotherapy of some type, if given early to patients with prostate cancer, can help to lower risk of progression of the disease. … READ MORE …

A better way to identify risk for metastasis?

According to a news report on the ScienceDaily web site, researchers in the UK have identified a subgroup of circulating tumor cells (CTCs) in patient’s blood that seem to be linked to risk for progression and spread of prostate cancer. … READ MORE …

Is IL-33 expression a key to risk for prostate cancer progression and metastasis?

According to a newly published article in the journal Scientific Reports, men who lose normal expression of a protein known as interleukin-33 or IL-33 are at higher risk for recurrence of their prostate cancer within 5 years than men who do not lose the expression of this biomarker. … READ MORE …